10.13.20

Outlook Therapeutics Announces Initiation of Open-Label Safety Study of Lytenava for Wet AMD

Source: Outlook Therapeutics

09.30.20

Outlook Therapeutics Provides Update on First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration

Source: Outlook Therapeutics

07.07.20

Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenava

Source: Outlook Therapeutics

12.05.18

Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps for ONS-5010 Clinical Strategy

Source: Outlook Therapeutics

View more stories